Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) are an emerging targeted therapy for various cancers, including breast cancer.
• Despite clinical promise, challenges like off-target toxicities and drug resistance limit ADC effectiveness due to intracellular mechanisms and limited antigen expression.
• The field of ADC-based breast cancer therapy is rapidly advancing with new drug designs and delivery strategies.

Purpose of the Study:

• To review the development of ADC-based targeted breast cancer therapy.
• To discuss the clinical translation and therapeutic potential of ADC drugs in breast cancer treatment.
• To highlight innovations addressing ADC limitations such as resistance and off-target effects.

Main Methods:

• Literature review of ADC development in breast cancer therapy.
• Analysis of clinical progress and challenges associated with ADC-based treatments.
• Examination of novel ADC strategies, including non-internalizing designs and tumor microenvironment targeting.

Main Results:

• ADCs show significant promise for targeted breast cancer therapy.
• Off-target toxicities and drug resistance remain key challenges.
• Innovative approaches like targeting the tumor microenvironment and extracellular delivery enhance ADC effectiveness and reduce resistance.

Conclusions:

• Novel ADC designs targeting the tumor microenvironment offer improved efficacy and reduced toxicity in breast cancer.
• Extracellular payload delivery mechanisms can overcome limitations of intracellular-acting ADCs.
• Continued development of ADCs holds significant potential for advancing breast cancer treatment.